OBJECTIVE: To assess the efficacy and tolerability of @entity903 20mg daily, for the treatment of @entity308 and @entity308 associated with @entity148 . METHOD: An open, non-comparative study undertaken at three centers in three cities of Pakistan. A total of 112 in- or out- @entity1 , presenting with a major @entity308 were included in the study. @entity308 was diagnosed according to DSM IV criteria and a Hamilton Rating Scale for @entity308 (HAMD-D) score of >18 on the first 17 items of the HAM-D-21. After a placebo washout period of 7 days, @entity1 were given a 20-mg fixed dose of @entity903 daily in the morning for a period of 6 weeks. After baseline, regular assessments were made at 1, 2, 4 and 6 weeks. Efficacy measures included the HAMD-D, the Clinical Anxiety Scale, The Clinical Global Impression Severity of Illness Scale (CGI-S), and the Clinical Global Impression Improvement Scale (CGI-I). Tolerability was assessed by any adverse event. The primary therapeutic outcome measures were @entity1 who achieved a 50% or greater reduction in HAMD-D score at the end of the treatment or achieved a reduction in final HAMD-D score of < or = 10 points. The final scores of 1 or 2 for CGI-S and CGI-I were considered as full clinical response. RESULTS: Of 112 cases evaluated, 57 were males and 55 females whose ages ranged from 18 to 65 years. There was a clear and statistically significant efficacy of @entity903 on all the major outcome variables. A total of 88% @entity1 achieved a reduction in the final HAMD-D score at the end of treatment. The total HAM-D score reduced to 10 or less in 73% @entity1 at 6 weeks and by this week 76% and 92% @entity1 achieved a score of 1 or 2 for CGI-S and CGI-I, respectively. The mean Clinical Anxiety Scale score reduced from 12.6 at the baseline to 4.4 at the end of treatment. Safety data was evaluated in all 112 @entity1 and @entity903 was well tolerated. Adverse events were experienced by 10% of @entity1 of whom 4% were dropped from the study. @entity390 was the commonest adverse event reported. CONCLUSION: The study shows that @entity903 is an effective, well-tolerated, and safe drug for the treatment of @entity308 .

Efficacy and tolerability of @entity903 20 mg daily in the treatment of @entity308 and @entity308 associated XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity308 :: ('MESH:D003866', 'Disease') :: ['Depression', 'depression', 'depressive episode'] @entity390 :: ('MESH:D009325', 'Disease') :: ['Nausea'] @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety']
@entity148 :: (MESH:D001008,Disease) :: ['anxiety']
